Tianjin Lisheng Pharmaceutical Co Ltd (002393) — Financial Flexibility Index
Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Financial Flexibility Index of 0.35x as of December 2025. Free cash flow of CN¥307.91 Million (operating CF CN¥287.81 Million minus capex CN¥20.11 Million) represents 0% of total liabilities (CN¥890.89 Million). Also explore Tianjin Lisheng Pharmaceutical Co Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Tianjin Lisheng Pharmaceutical Co Ltd Financial Flexibility Index (2007–2025)
Historical Financial Flexibility Index trend for Tianjin Lisheng Pharmaceutical Co Ltd across 19 annual periods. Check asset allocation strategy of Tianjin Lisheng Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
Year-by-year free cash flow to debt coverage for Tianjin Lisheng Pharmaceutical Co Ltd. For the full company profile including market capitalisation, see 002393 company net worth.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.55x | CN¥489.31 Million | CN¥451.85 Million | CN¥890.89 Million | ▲ +281.2% |
| 2024 | 0.14x | CN¥142.01 Million | CN¥88.26 Million | CN¥985.54 Million | ▼ -53.4% |
| 2023 | 0.31x | CN¥271.23 Million | CN¥209.51 Million | CN¥877.17 Million | ▼ -21.8% |
| 2022 | 0.40x | CN¥372.30 Million | CN¥331.38 Million | CN¥941.66 Million | ▲ +8.4% |
| 2021 | 0.36x | CN¥284.58 Million | CN¥196.34 Million | CN¥780.42 Million | ▲ +48.3% |
| 2020 | 0.25x | CN¥177.03 Million | CN¥76.37 Million | CN¥720.09 Million | ▼ -41.4% |
| 2019 | 0.42x | CN¥358.78 Million | CN¥268.33 Million | CN¥855.85 Million | ▲ +10.6% |
| 2018 | 0.38x | CN¥267.12 Million | CN¥162.69 Million | CN¥704.85 Million | ▼ -0.5% |
| 2017 | 0.38x | CN¥229.34 Million | CN¥179.25 Million | CN¥602.32 Million | ▼ -42.3% |
| 2016 | 0.66x | CN¥310.80 Million | CN¥173.60 Million | CN¥470.60 Million | ▼ -27.9% |
| 2015 | 0.92x | CN¥402.73 Million | CN¥198.13 Million | CN¥439.50 Million | ▼ -14.7% |
| 2014 | 1.07x | CN¥362.89 Million | CN¥72.24 Million | CN¥337.89 Million | ▼ -46.9% |
| 2013 | 2.02x | CN¥602.72 Million | CN¥289.62 Million | CN¥298.20 Million | ▼ -37.0% |
| 2012 | 3.21x | CN¥475.07 Million | CN¥250.72 Million | CN¥148.13 Million | ▼ -31.6% |
| 2011 | 4.69x | CN¥300.53 Million | CN¥134.58 Million | CN¥64.07 Million | ▲ +41.2% |
| 2010 | 3.32x | CN¥256.24 Million | CN¥186.55 Million | CN¥77.12 Million | ▲ +539.3% |
| 2009 | 0.52x | CN¥213.74 Million | CN¥196.14 Million | CN¥411.26 Million | ▼ -26.5% |
| 2008 | 0.71x | CN¥191.45 Million | CN¥126.59 Million | CN¥270.58 Million | ▲ +65.5% |
| 2007 | 0.43x | CN¥188.86 Million | CN¥174.94 Million | CN¥441.87 Million | — |